Which medications in the drug class Phosphodiesterase-5 Enzyme Inhibitors are used in the treatment of Benign Prostatic Hyperplasia (BPH)?

Updated: Feb 19, 2021
  • Author: Levi A Deters, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

Phosphodiesterase-5 Enzyme Inhibitors

These agents mediate smooth muscle relaxation in the lower urinary tract, thus improving the symptoms of BPH.

Tadalafil (Cialis)

PDE5 selective inhibitor. Inhibition of PDE5 increases cGMP activity, which increases vasodilatory effects of nitric oxide. Sexual stimulation is necessary to activate response. Tadalafil has been approved by the FDA for the treatment of BPH signs and symptoms.

PDE5 inhibition has been shown to induce smooth muscle relaxation in the lower urinary tract. It has also been approved for the treatment of simultaneous BPH and ED.

Increased sensitivity for erections may last 36 h with intermittent dosing. Low-dose daily dosing may be recommended for more frequent sexual activity (ie, twice weekly); men can attempt sexual activity at anytime between daily doses.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!